Medullary Thyroid Carcinoma (MTC) Cell Models for Research

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor arising from parafollicular C cells. According to the World Health Organization (WHO) classification (5th edition, 2022), MTC accounts for approximately 1-2% of all thyroid cancers but contributes disproportionately to thyroid cancer mortality. The global incidence is estimated at 0.14-0.44 per 100,000 person-years, with a slight female predominance (SEER data, NCI).

MTC occurs in two forms: sporadic (75-80%) and hereditary (20-25%) as part of multiple endocrine neoplasia type 2 (MEN2) syndromes. Hereditary MTC is caused by germline activating mutations in the RET proto-oncogene (OMIM 164761). Sporadic MTC often harbors somatic RET mutations (up to 60-70%) and less frequently RAS mutations (HRAS, KRAS, NRAS) (COSMIC).

The 5-year survival rate for localized MTC is 95%, but for distant metastatic disease it drops to 40% (NCI SEER data, 2010-2019). The 10-year survival for advanced MTC is less than 20%. The main clinical challenges are early detection, limited efficacy of systemic therapies (tyrosine kinase inhibitors like vandetanib and cabozantinib), and the lack of curative options for metastatic disease.

MTC is an ideal model for studying oncogenic signaling because it is driven by a single dominant oncogene (RET) in the majority of cases. This genetic simplicity allows for precise mechanistic studies and targeted therapeutic approaches. The availability of well-characterized cell lines (TT, MZ-CRC-1) and patient-derived xenografts (PDX) facilitates translational research.

Key open questions include:

• • Mechanisms of resistance to RET inhibitors (e.g., selpercatinib, pralsetinib) – acquired resistance mutations in RET (e.g., G810S, V804M) (NCI, ClinVar).
• • The role of RAS mutations in RET-wild-type MTC.
• • The interaction between RET signaling and the tumor microenvironment.
• • Identification of synthetic lethal targets for MTC with specific genetic backgrounds.

Public datasets from TCGA (Thyroid Cancer, THCA) and COSMIC provide mutation frequencies and expression profiles, but functional validation requires gene-edited cell models.

MTC pathogenesis is primarily driven by constitutive activation of the RET receptor tyrosine kinase. The following pathways are critical:

1. RET signaling pathway:

• • Ligand-independent dimerization (hereditary) or point mutations (sporadic) lead to constitutive kinase activity.
• • Activation of downstream cascades: RAS/MAPK, PI3K/AKT, JAK/STAT, and PLCγ.
• • Result: increased cell proliferation, survival, and migration.

2. RAS/MAPK pathway:

• • In RET-wild-type MTC, activating mutations in HRAS, KRAS, or NRAS (codons 12, 13, 61) are found in ~25% of cases (COSMIC).
• • These mutations lead to sustained ERK signaling, promoting tumor growth.

3. PI3K/AKT pathway:

• • Often activated downstream of RET or RAS, leading to anti-apoptotic signals.
• • PTEN loss or mutation is rare but may contribute to aggressive behavior.

4. Wnt/β-catenin pathway:

• • Aberrant activation has been reported in some MTCs, contributing to epithelial-mesenchymal transition (EMT) and metastasis.

5. Cell cycle regulation:

• • Loss of CDKN2C (p18) or CDKN2A (p16) is observed in a subset of MTCs, leading to uncontrolled cell cycle progression.

Data sources: TCGA (THCA), COSMIC (v96), ClinVar.

The key deregulated networks in MTC include:

• • RET-RAS-MAPK axis: Central to tumorigenesis. Key nodes: RET, GRB2, SOS, RAS, RAF, MEK, ERK.
• • PI3K-AKT-mTOR axis: Activated via RET or RAS. Key nodes: PI3K, PDK1, AKT, mTOR, S6K.
• • JAK-STAT pathway: RET can activate STAT3, promoting cell survival and immune evasion.
• • Focal adhesion and migration: RET activates FAK and SRC, enhancing invasion.
• • Angiogenesis: RET upregulates VEGF and FGF, promoting tumor vascularization.
• • DNA damage response: TP53 mutations impair genomic stability, leading to accumulation of additional alterations.
• • Epigenetic regulators: Histone modifiers (e.g., EZH2) may be overexpressed, leading to silencing of tumor suppressors.

Organoids: Patient-derived MTC organoids have been established and retain RET mutations and secretory features (calcitonin production). They are useful for drug testing and personalized medicine studies. However, organoid culture is technically challenging and has limited throughput compared to cell lines.

Animal models for MTC include:

• • Patient-derived xenografts (PDX): Implantation of MTC tumor fragments into immunodeficient mice. These retain the genetic and histologic features of the original tumor, but require viable tumor tissue and are time-consuming.
• • Genetically engineered mouse models (GEMM):
• • RET C634R knock-in mice develop MTC with high penetrance.
• • RET M918T knock-in mice develop early-onset MTC.
• • Conditional RET overexpression models using thyroglobulin promoter.
• • Induced models: Chemical carcinogens (e.g., N-nitroso compounds) can induce MTC in rats, but are less relevant to human disease.
• • Syngeneic models: Mouse MTC cell lines (e.g., 6-13) can be transplanted into immunocompetent mice for immunotherapy studies.

CRISPR-based gene editing has revolutionized MTC research by enabling the creation of isogenic cell lines with precise genetic modifications. These models are essential for studying the functional consequences of specific mutations and for drug development.

Examples of gene-edited MTC models:

• • RET knockout in TT cells: Ablation of RET eliminates downstream signaling, demonstrating oncogene addiction.
• • RET M918T knock-in in RET-wild-type MTC cells (e.g., using a RET-negative background) to study the effect of the most common somatic mutation.
• • RAS mutant knock-in (e.g., HRAS Q61R) in RET-wild-type MTC cells to model RAS-driven MTC.
• • CDKN2C knockout to study cell cycle deregulation.
• • TP53 knockout to model aggressive, therapy-resistant MTC.

Commercially available, sequence-verified gene-edited cell lines (e.g., from specialized CROs) provide researchers with validated tools, reducing the time and cost of generating these models in-house. These models are ideal for:

• • Target validation
• • Drug screening
• • Mechanistic studies
• • Resistance studies

Note: No specific company names are mentioned, but such models are available from commercial sources.

Gene-edited cells are used to validate the role of specific genes in MTC tumorigenesis. For example:

• • RET knockout in TT cells leads to reduced proliferation and increased apoptosis, confirming RET as a driver.
• • HRAS Q61R knock-in in RET-wild-type cells induces transformation and MAPK activation, demonstrating the oncogenic potential of RAS mutations.
• • CDKN2C knockout leads to accelerated cell cycle progression, supporting its tumor suppressor role.
• • CRISPR screens (loss-of-function) can identify genes essential for MTC cell survival, revealing novel therapeutic targets.

Isogenic cell line pairs (e.g., RET wild-type vs. RET M918T knock-in) are powerful tools for drug screening:

• • They allow selective testing of RET inhibitors (e.g., selpercatinib, pralsetinib) in a controlled genetic background.
• • Resistance models can be generated by exposing cells to increasing drug concentrations or by introducing known resistance mutations (e.g., RET G810S) via CRISPR.
• • These models help identify mechanisms of acquired resistance and guide combination therapy strategies.
• • High-throughput screening using gene-edited cells can identify compounds that selectively kill MTC cells with specific mutations.

CRISPR-based synthetic lethality screens in MTC cells can identify novel biomarkers and therapeutic vulnerabilities:

• • For example, in RET-mutant MTC, targeting the MAPK pathway may be synthetically lethal with certain DNA repair inhibitors.
• • Gene-edited models can be used to identify secreted proteins (e.g., calcitonin, CEA) as biomarkers for monitoring treatment response.
• • Knockout of genes involved in drug metabolism can reveal biomarkers of resistance.
• • Transcriptomic and proteomic profiling of isogenic pairs can uncover novel diagnostic markers.